Immunohistochemistry of affected tissue may guide cGVHD treatment decisions

K. M. Williams, L. W. Ostrow, D. M. Loeb, T. Chung, R. D. Cohn, A. M. Corse, A. L. Mammen, A. R. Chen

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Chronic graft-vs-host disease (cGVHD) myositis is a rare complication of hematopoietic SCT, for which the pathogenesis and optimal therapy are unclear. We performed immunohistochemistry on muscle biopsies from pediatric cGVHD myositis and typical cases of autoimmune dermatomyositis and polymyositis. The immunostaining pattern of cGVHD myositis was distinct from that of typical cases of autoimmunity. There was a high proportion of CD20 and CD68+ cells, and the best therapeutic response was achieved with rituximab (anti-CD20). These results suggest that cGVHD myositis may be mediated by different leukocytes than similar autoimmune diseases and that treatment may be optimized by targeting the specific cellular infiltrates identified in affected tissue.

Original languageEnglish (US)
Pages (from-to)731-733
Number of pages3
JournalBone Marrow Transplantation
Issue number5
StatePublished - May 2012
Externally publishedYes


  • CD20, myositits
  • cGVHD
  • rituximab

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Immunohistochemistry of affected tissue may guide cGVHD treatment decisions'. Together they form a unique fingerprint.

Cite this